Sidoti Csr Analysts Decrease Earnings Estimates for Balchem Co. (NASDAQ:BCPC)

Balchem Co. (NASDAQ:BCPC) – Stock analysts at Sidoti Csr dropped their Q1 2025 earnings estimates for Balchem in a research note issued on Wednesday, October 9th. Sidoti Csr analyst K. May now expects that the basic materials company will post earnings per share of $1.16 for the quarter, down from their prior forecast of $1.18. The consensus estimate for Balchem’s current full-year earnings is $3.96 per share. Sidoti Csr also issued estimates for Balchem’s Q2 2025 earnings at $1.18 EPS, Q3 2025 earnings at $1.21 EPS, Q4 2025 earnings at $1.20 EPS and FY2025 earnings at $4.75 EPS.

Several other equities research analysts also recently issued reports on BCPC. HC Wainwright increased their price objective on shares of Balchem from $170.00 to $185.00 and gave the stock a “buy” rating in a research report on Wednesday, July 31st. StockNews.com cut Balchem from a “buy” rating to a “hold” rating in a report on Monday, July 29th.

Balchem Price Performance

Shares of BCPC opened at $172.21 on Friday. The stock has a 50 day simple moving average of $170.67 and a 200 day simple moving average of $161.10. Balchem has a 52-week low of $110.74 and a 52-week high of $186.03. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.79 and a current ratio of 2.83. The firm has a market capitalization of $5.58 billion, a PE ratio of 48.65, a P/E/G ratio of 5.43 and a beta of 0.65.

Balchem (NASDAQ:BCPC) last posted its earnings results on Friday, July 26th. The basic materials company reported $0.98 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.95 by $0.03. The firm had revenue of $234.08 million during the quarter, compared to analysts’ expectations of $241.26 million. Balchem had a return on equity of 10.94% and a net margin of 12.52%.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of BCPC. Bessemer Group Inc. boosted its holdings in shares of Balchem by 568.9% in the 1st quarter. Bessemer Group Inc. now owns 301 shares of the basic materials company’s stock valued at $47,000 after buying an additional 256 shares during the last quarter. GAMMA Investing LLC increased its stake in shares of Balchem by 18.0% during the 1st quarter. GAMMA Investing LLC now owns 473 shares of the basic materials company’s stock worth $73,000 after purchasing an additional 72 shares during the last quarter. TD Asset Management Inc bought a new stake in shares of Balchem in the 2nd quarter valued at about $200,000. Heritage Family Offices LLP bought a new stake in shares of Balchem in the 2nd quarter valued at about $206,000. Finally, Sage Rhino Capital LLC acquired a new stake in Balchem in the 2nd quarter valued at about $207,000. 87.91% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, SVP Gunsteren Job Leonard Van sold 7,750 shares of Balchem stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $180.05, for a total value of $1,395,387.50. Following the sale, the senior vice president now directly owns 8,540 shares in the company, valued at $1,537,627. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 1.25% of the company’s stock.

Balchem Company Profile

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.